Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DiffronC
- Development stage
- Preclinical
- Lead developer
- Regen BioPharma
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
01
Overview
DiffronC is an oligonucleotide-based gene therapy developed by Regen BioPharma that utilizes proprietary small interfering RNA (siRNA) technology to induce differentiation of cancer stem cells. Its mechanism involves silencing nuclear receptor targets—specifically those that maintain stem cells in an undifferentiated state—thereby promoting the maturation of blood-forming stem and progenitor cells into functional blood cells. This approach is designed as a differentiation therapy for hematological malignancies such as leukemia and myelodysplastic syndromes where normal cellular maturation is blocked. Preclinical data have demonstrated its ability to drive differentiation in vitro and provide proof-of-concept for its use in treating disorders characterized by impaired blood cell development[8][10][6].
- Brand names
- DiffronC
- Other names
- IDO-silenced cancer immunotherapeutic - Regen BiopharmaNR2F6 inhibitors - Regen BioPharmaNR-2F6 inhibitors - Regen BioPharmaNR 2F6 inhibitors - Regen BioPharmaNR2F6 T cell immunotherapyNR-2F6 T cell immunotherapyNR 2F6 T cell immunotherapyNR2F6-silenced cancer therapeutics - Regen BioPharmaNR-2F6-silenced cancer therapeutics - Regen BioPharmaNR 2F6-silenced cancer therapeutics - Regen BioPharmaucVAXUniversal donor cell therapy - Regen BioPharma
02
Targets
NR2F6 (Nuclear receptor subfamily 2 group F member 6)
Beyond the preview
Go deeper on DiffronC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DiffronC.